Clinical Trials
69 trialsA Study to Find the Highest Dose of Cedazuridine and Decitabine Combination With Filgrastim as a Treatment Option After Hematopoietic Stem Cell Transplant in Children With High-Risk Acute Myeloid Leukemia
National Cancer Institute (NCI)
CPX-351 in Treating Patients With Relapsed or Refractory High Risk Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia
M.D. Anderson Cancer Center
Liposomal Cytarabine, Daunorubicin, and Gemtuzumab Ozogamicin for the Treatment of Relapsed Refractory Pediatric Patients With Acute Myeloid Leukemia
M.D. Anderson Cancer Center
Navitoclax in Relapsed or Refractory High-Risk Myelodysplastic Syndrome
Thomas Jefferson University
Testing a New Chemotherapy Drug, KRT-232 (AMG-232) in Combination With Decitabine and Venetoclax in Patients With Acute Myeloid Leukemia
National Cancer Institute (NCI)
SKB410 for Injection in Solid Tumors
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
A Study of SKB315 in Patients With Advanced Solid Tumors
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
A Study of SKB518 in Patients With Advanced Solid Tumors
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
SKB445 for Injection in Solid Tumors
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
A Study of SKB107 in Advanced Solid Tumors With Bone Metastases
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
Ipilimumab and Decitabine in Treating Patients With Relapsed or Refractory Myelodysplastic Syndrome or Acute Myeloid Leukemia
National Cancer Institute (NCI)
Evaluate the Safety, Tolerability, Pharmacokinetics of DR30206 in Patients With Advanced or Metastatic Solid Tumors
Zhejiang Doer Biologics Co., Ltd.
Pevonedistat and Decitabine in Treating Patients With High Risk Acute Myeloid Leukemia
City of Hope Medical Center
Navitoclax, Venetoclax, and Decitabine for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia Previously Treated With Venetoclax
City of Hope Medical Center
A First-in-Human Study of ALK-N001 for Injection in Patients With Advanced Solid Tumors
Zhejiang Anglikang Pharmaceutical Co., Ltd.
A Clinical Study of SHR-9539 in Patients With Multiple Myeloma
Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Palbociclib and Sorafenib, Decitabine, or Dexamethasone in Treating Patients With Recurrent or Refractory Leukemia
M.D. Anderson Cancer Center
Bortezomib, Sorafenib Tosylate, and Decitabine in Treating Patients With Acute Myeloid Leukemia
National Cancer Institute (NCI)
To Evaluate the Safety, Tolerance and Pharmacokinetics of BAT8007 for Injection in Patients With Advanced Solid Tumors
Bio-Thera Solutions
Genetically Modified T Cells and Decitabine in Treating Patients With Recurrent or Refractory Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
Roswell Park Cancer Institute
Assessment of Safety, Tolerability and Pharmacokinetics With BAT8010 for Injection in Advanced Malignant Solid Tumors Patients
Bio-Thera Solutions
Safety and Efficacy Study of TX103 CAR-T Cell Therapy for Recurrent or Progressive Grade 4 Glioma.
Tcelltech Inc.
Tazemetostat and Palbociclib With CPX-351for R/R AML
Thomas Jefferson University
Pembrolizumab and Decitabine With or Without Venetoclax in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome That Is Newly-Diagnosed, Recurrent, or Refractory
City of Hope Medical Center
DEC-205/NY-ESO-1 Fusion Protein CDX-1401, Poly ICLC, Decitabine, and Nivolumab in Treating Patients With Myelodysplastic Syndrome or Acute Myeloid Leukemia
Roswell Park Cancer Institute
Evaluation of T320, an Anti-Tissue Factor Antibody-Drug Conjugate, in Patients With Advanced Solid Tumors
Nanolattix Biotechnology Co., Ltd.
Assessing Radio-hybrid Prostate Specific Membrane Antigen (rhPSMA-7.3) (18F) in Healthy Volunteers and Subjects With Prostate Cancer
Blue Earth Diagnostics
Evaluate the Safety, Tolerability and Pharmacokinetic Characteristics of BAT8008 for Injection
Bio-Thera Solutions
Atezolizumab and Varlilumab in Combination With Radiation Therapy for NSCLC
Rutgers, The State University of New Jersey
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of YK012
Excyte Biopharma Ltd
A Study of YKST02 in Participants With Relapsed or Refractory Multiple Myeloma
Excyte Biopharma Ltd
A Phase I Study of SIM0505 in Participants With Advanced Solid Tumors
NextCure, Inc.
Sapu003 in Advanced mTOR-sensitive Solid Tumors
SAPU NANO (US) LLC
Decitabine in Combination With Standard of Care Therapy for the Treatment of Surgically Resectable HPV-Negative Head and Neck Cancer
Mayo Clinic
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), and Preliminary Efficacy of BC2027 in Patients With Advanced Solid Malignancies
Biocity Biopharmaceutics Co., Ltd.
SIM0610-101
Jiangsu Simcere Pharmaceutical Co., Ltd.
A Phase 1 Study of CG009301 for Injection in Adult Subjects With Recurrent or Refractory Haematological Malignancies
Cullgen (Shanghai),Inc
A Clinical Study of SHR-A1811(sc) Subcutaneous Injection in Patients With Solid Tumor
Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Tegavivint for the Treatment of Relapsed or Refractory Leukemia
M.D. Anderson Cancer Center
A Clinical Trial of SIBP-A13 Injection in the Treatment of Advanced Malignant Solid Tumor Patients.
Shanghai Institute Of Biological Products
A Study of RC108-ADC in Subjects With Advanced Malignant Solid Tumors
RemeGen Co., Ltd.
Evaluate the Safety, Tolerability and Pharmacokinetic Characteristics of BAT8006 for Injection
Bio-Thera Solutions
GenSci143 in Participants With Advanced Solid Tumors
Changchun GeneScience Pharmaceutical Co., Ltd.
A Study of BRY812 for Injection Alone in Subjects With Advanced Malignancies
BioRay Pharmaceutical Co., Ltd.
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of GenSci140 in Participants With Advanced Solid Tumors
Changchun GeneScience Pharmaceutical Co., Ltd.
KZR-261 in Subjects With Advanced Solid Malignancies
Kezar Life Sciences, Inc.
Solid Tumors
Jiangsu Simcere Pharmaceutical Co., Ltd.
Phase I Clinical Study of JS203 in Patients With Relapsed/Refractory B-cell Non-Hodgkin's Lymphoma
Shanghai Junshi Bioscience Co., Ltd.
CAR-DC Vaccine and ICIs in Local Advanced/Metastatic Solid Tumors
Chinese PLA General Hospital
An Open-label, Multi-center, Dose-escalation and Cohort Expansion Phase I/IIa Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetic Profile and Efficacy of ACR246 in Patients With Advanced Solid Tumors
Hangzhou Adcoris Biopharmacy Co., Ltd